OncoMatch/Clinical Trials/NCT06675513
Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer
Is NCT06675513 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name: for crc (colorectal cancer).
Treatment: An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name: — This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (WD-01) in the metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: GUCY2C overexpression (IHC ≥1+ in >40% of tumor area)
Immunohistochemistry (IHC) assessment shows GCC expression in tumor lesions of ≥1+ in an average of over 40% of the area
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: cytotoxic chemotherapy
Patients with metastatic colorectal cancer who have failed second-line treatment
Cannot have received: small molecule chemotherapy
Receipt of small molecule chemotherapy ... within 14 days prior to cell collection for enrollment
Cannot have received: targeted agent
Receipt of ... targeted agents ... within 14 days prior to cell collection for enrollment
Cannot have received: monoclonal antibody
Receipt of ... monoclonal antibodies within 14 days prior to cell collection for enrollment
Cannot have received: investigational drug
Receipt of ... other investigational drugs ... within 14 days prior to cell collection for enrollment
Lab requirements
Blood counts
Hemoglobin (HB) ≥80 g/L, Absolute Neutrophil Count (ANC) ≥1.5 × 10^9/L, Platelets (PLT) ≥80 × 10^9/L, Lymphocytes (LY) ≥0.5 × 10^9/L
Kidney function
Serum Creatinine ≤1 × ULN, Creatinine Clearance Rate >40 mL/min (by Cockcroft-Gault formula)
Liver function
Total Bilirubin ≤2.0 × ULN; ALT and AST ≤2.5 × ULN
Cardiac function
Left ventricular ejection fraction >55%
Normal function of major organs, meeting the following criteria: ... Hematology parameters ... Biochemistry parameters ... Left ventricular ejection fraction >55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify